title: Randomized trial in multiparous patients: investigating a single vs. two-dose regimen of intravaginal misoprostol for induction of labor.
abstract: BACKGROUND
  Multiparous patients have a higher risk of hyperstimulation and uterine rupture than nulliparous patients. The minimum possible dose of uterotonic drug should be used in induction of labor for multiparous patients to avoid excessive uterine activity, which could increase both maternal and fetal risks.
  
  
  METHODS
  One hundred and four women were randomized to either a single dose of 50 micro g of intravaginal misoprostol in 24 h, or two consecutive doses of intravaginal 50 micro g misoprostol 6 h apart.
  
  
  RESULTS
  The mean induction to delivery interval (789 min [95% CI: 637-941] vs. 576 min [95% CI: 484-667], p = 0.018) and delivery rate within 12 h (63% vs. 83%, p = 0.035) were higher in the two-dose group. The oxytocin augmentation rate (14% vs. 2%, p = 0.03) was higher in the single-dose group. There was a higher rate of clinician input related to suspicious cardiotocographic readings in the single-dose arm (p = 0.04). There was no statistical difference (p > 0.05) between the one- and two-dose regimens with respect to the rates of tachysystole (21% vs. 15%), hyperstimulation (3.9% vs. 0%), and meconium staining at delivery (9.8% vs. 13.2%).
  
  
  CONCLUSIONS
  The two-dose regimen was most efficient, but both regimens were well tolerated by the fetuses.
authors.affiliation: Department of Obstetrics & Gynecology, Royal Free & University College London Medical School, University College London, London, UK. a.lokugamage@ucl.ac.uk
authors.forename: Amali U
authors.initials: AU
authors.lastname: Lokugamage
authors.forename: Sophie F
authors.initials: SF
authors.lastname: Forsyth
authors.forename: Keith R
authors.initials: KR
authors.lastname: Sullivan
authors.forename: Hazem
authors.initials: H
authors.lastname: El Refaey
authors.forename: Charles H
authors.initials: CH
authors.lastname: Rodeck
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D015148:Cardiotocography / Q000187:drug effects; D020070:Cervical Ripening / Q000187:drug effects; D005260:Female; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D007743:Labor, Obstetric; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D010120:Oxytocics / Q000008:administration & dosage* / Q000009:adverse effects; D010121:Oxytocin / Q000627:therapeutic use; D010298:Parity; D011247:Pregnancy; D011256:Pregnancy Outcome; D012449:Safety
chemical_list: D010120:Oxytocics; D016595:Misoprostol; D010121:Oxytocin